Tech Session VII: Delivery to the Nervous System II
Novel triple-drug cocktail for glioblastoma exhibits potent synergistic antitumoral effects
Friday, July 18, 2025
9:27 AM - 9:38 AM EDT
Location: 119 A
Introduction: Glioblastoma (GBM) is the most common and lethal primary brain cancer and remains incurable mainly due to limited drug action at the tumor site, systemic toxicity, and resistance mechanisms including chemoresistance and immunosuppression. Indeed, GBM tumors often display high levels of DNA repair enzyme O6-methylguanine DNA methyltransferase (MGMT) to correct the damage induced by the standard-of-care drug temozolomide (TMZ), leading to tumor cell survival and poor prognosis (1). Moreover, GBM’s immunosuppressive and “cold” nature renders most immunotherapies ineffective (2).
Learning Objectives:
At the completion of this activity, participants will know
Understand that combining drugs can help achieve a synergistic and powerful anticancer treatment.
Explain the need for a multi-modal approach to defeat challenging cancers like glioblastoma.
Mansoor Amiji – University Distinguished Professor, Northeastern University, Boston, Massachusetts, USA; Hélder Santos – Group Leader/Principal Investigator, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands; Bruno Sarmento – Group Leader/Principal Investigator, i3S – Institute for Research and Innovation in Health, University of Porto, Portugal
